deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT03823131

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

The Trifecta Study: Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

Sponsor: Chase Heaton, MD

Conditions Metastatic Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma Unresectable Head and Neck Squamous Cell Carcinoma
Interventions CORVax Epacadostat ImmunoPulse Pembrolizumab Tavokinogene telseplasmid
Updated 13 times since 2019 Last updated: Apr 17, 2023 Started: May 2, 2019 Primary completion: Jul 31, 2022 Completion: Jul 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Treatment Ineffective

Other Metastatic Head and Neck Squamous Cell Carcinoma trials with similar outcome

Browse all Metastatic Head and Neck Squamous Cell Carcinoma trials

This PHASE2 trial investigates Metastatic Head and Neck Squamous Cell Carcinoma and Recurrent Head and Neck Squamous Cell Carcinoma and is currently terminated or withdrawn. Chase Heaton, MD leads this study, which shows 13 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2019 – ~Dec 2019 · 10 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~Sep 2020 · 5 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~May 2022 · 4 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Jun 2023 · 9 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jun 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Sep 2022 — Jun 2023 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  5. May 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

▶ Show 8 earlier versions

  1. Jan 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  4. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Apr 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  6. Feb 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  7. Dec 2019 — Feb 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Feb 2019 — Dec 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chase Heaton, MD
  • Incyte Corporation
  • OncoSec Medical Incorporated
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations